France Medical Device Regulations 2026: What Manufacturers Need to Know
Expanding into France in 2026 requires full compliance with the EU Medical Device Regulation (EU MDR 2017/745), EUDAMED registration requirements, and oversight from France’s national competent authority, ANSM. As one of Europe’s largest medical device markets, France offers significant commercial opportunities. However, regulatory expectations under MDR are more rigorous than ever, particularly around clinical evidence, post-market surveillance, and data transparency.
Below is a concise guide to medical device registration in France and what manufacturers should prioritize.
Who Regulates Medical Devices in France?
Medical devices in France are regulated by the Agence nationale de sécurité du médicament et des produits de santé (ANSM). ANSM is responsible for market surveillance, vigilance reporting, clinical investigation approvals, advertising oversight for certain device categories, and enforcement of EU MDR requirements at the national level. While MDR harmonizes medical device regulations across the EU, ANSM plays a critical supervisory role within France.
CE Marking Under EU MDR
CE marking under MDR is mandatory to place a medical device on the French market. Devices are classified as Class I, IIa, IIb, or III based on risk. Class I devices that are non-sterile, have no measuring function, and are not reusable surgical instruments may be self-declared by the manufacturer. All other device classes require Notified Body involvement in the conformity assessment process. Clinical evaluation requirements are significantly strengthened under MDR, and post-market surveillance obligations are expanded for all device classes. Once CE marked, devices can be marketed across all EU and EEA member states, including France.
EUDAMED Registration: Critical 2026 Deadlines
Under MDR, manufacturer and device registration flows through EUDAMED. From May 28, 2026, EUDAMED registration is mandatory for four confirmed functional modules: economic operator registration, UDI and device registration, Notified Bodies and certificates, and market surveillance. Prior to this date, registration remains voluntary.
From May 28, 2026, new devices must be registered in EUDAMED before being placed on the market. Devices already on the market before that date must be registered in EUDAMED by November 28, 2026. All manufacturers must register as an economic operator, obtain a Single Registration Number (SRN), upload required UDI and device data, and maintain accurate vigilance records.
Non-EU manufacturers must appoint an EU Authorized Representative, who assumes defined regulatory obligations under MDR.
Manufacturers should also be aware that the European Commission is actively reviewing the MDR and IVDR frameworks with the aim of targeted simplification. Regulatory developments should be monitored throughout 2026, as amendments may affect specific compliance obligations in the coming years.
France-Specific Requirements
Although MDR is EU-wide, France maintains national requirements that manufacturers must address.
Labeling and Instructions for Use must be in French. Vigilance reporting must align with MDR timelines and be submitted through the appropriate channels under ANSM oversight.
France also enforces stricter rules than many EU member states around medical device advertising, particularly for devices marketed directly to consumers. Manufacturers should ensure promotional materials comply with ANSM advertising requirements before commercialization.
Clinical investigations conducted in France require ANSM approval and ethics committee review in accordance with MDR documentation and safety reporting standards.
Reimbursement Considerations
Manufacturers seeking reimbursement under the French national health system should be aware of the specific national pathway. The CNEDiMTS (Commission Nationale d’Evaluation des Dispositifs Médicaux et des Technologies de Santé) evaluates devices for reimbursement eligibility, and pricing is subsequently negotiated with the CEPS (Comité Économique des Produits de Santé). Regulatory approval and reimbursement are separate processes, and manufacturers should plan for both early in their market access strategy.
Post-Market Surveillance and Ongoing Compliance
Post-market compliance is a major focus under MDR and is actively monitored by ANSM. Manufacturers must maintain a documented Post-Market Surveillance plan, Periodic Safety Update Reports for Class IIb and III devices (Class IIa devices have separate periodic reporting obligations under MDR Article 86), UDI-based traceability systems, and Field Safety Corrective Action procedures. For regulatory teams managing compliance across multiple EU markets, centralized data and workflow management is essential for maintaining audit readiness.
France Medical Device Market Overview
France remains one of the largest medical device markets in Europe, with strong demand in orthopedics, cardiovascular and implantable devices, minimally invasive technologies, and digital health and Software as a Medical Device. Manufacturers entering the French market must align regulatory strategy with reimbursement planning to ensure long-term commercial success.
Key Takeaways for 2026
To successfully commercialize a medical device in France, manufacturers should ensure full compliance with EU MDR, obtain valid CE marking, complete EUDAMED economic operator and device registration ahead of the May 28, 2026 mandatory deadline (with legacy devices requiring registration by November 28, 2026), appoint an EU Authorized Representative if located outside the EU, meet French language and advertising requirements, implement structured post-market surveillance and vigilance processes including PSURs where required under MDR Article 86, align regulatory planning with the CNEDiMTS and CEPS reimbursement pathway, and monitor ongoing European Commission MDR simplification discussions for developments that may affect compliance obligations.
As regulatory scrutiny increases across Europe, proactive planning and centralized regulatory intelligence are critical for accelerating market access while reducing compliance risk.
Looking to streamline EU MDR and multi market compliance?
Explore how RegDesk’s Regulatory Information Management System helps teams centralize submissions, manage post market surveillance, and stay audit ready across global markets.
